Mechanistically, Gliclazide inhibited the proliferation of lung adenocarcinoma cells possibly by targeting CCNB1, CCNB1, CDK1 and AURKA to induce cell cycle arrest and apoptosis. Here, CDK1 is linked to lung adenocarcinoma.